Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Clin |
RCV001789732 | SCV002032141 | pathogenic | Glycogen storage disease, type II | 2024-05-21 | reviewed by expert panel | curation | The NM_000152.5:c.827_845del (p.Ile276ThrfsTer32) variant in GAA is a frameshift variant predicted to cause a premature stop codon in biologically-relevant-exon 5 out of 20, leading to nonsense mediated decay in a gene in which loss-of-function is an established disease mechanism (PVS1). One patient with clinical features consistent with late onset Pompe disease, elevated creatine kinase, and histological features of Pompe disease was reported to be compound heterozygous for the variant and another variant in GAA that has been classified as pathogenic by the ClinGen Lysosomal Diseases Variant Curation Expert Panel, c.2238G>C (p.Trp746Cys) (ClinVar variation ID: 265160, SCV002032122.1). The variants were confirmed to be in trans by parental DNA analysis (PMID 27099502) (PM3). This variant is absent in gnomAD v2.1.1 (PM2_Supporting). GAA-specific ACMG/AMP criteria met, as specified by the ClinGen Lysosomal Diseases Variant Curation Expert Panel (Specification Version 2.0): PVS1, PM3, PM2_Supporting (Classification approved by the ClinGen Lysosomal Diseases Variant Curation Expert Panel on May 21, 2024). |